



RECEIVED

JUN 1 3 2002

SUBMISSION UNDER MPEP 609 D

Application Number
Filing Date
First Named Inventor
Group Art Unit
Examiner Name
Attorney Docket Number

Light Fig. 1600 2900
Wiegand
Wiegand
JBP-571


Page 1 of 1

U.S. PATENT DOCUMENTS U.S. Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear Name of Patentee or Applicant Kind Code² Examiner Cite of Cited Document Initials (if known) Number No.1 Johnson & Johnson Consumer USSN 10/012,626 KG Companies, Inc. our docket JBP-575 Johnson & Johnson Consumer USSN 10/012,627 Companies, Inc. our docket JBP-570 Johnson & Johnson Consumer USSN 09/676,876 p.10 of JBP-575 Companies, Inc. Our docket JBP-521 p.24 of JBP-571 USSN 60/256,812 Johnson & Johnson Consumer Companies, Inc. KG Our docket JBP-531

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign Pa	ntent Documer	nt KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁸
	<u> </u>						
		-		 	1		
		4-4-1					
				 	+		
				<u> </u>	<u> </u>		
		OTHER PRIOR ART - N	ON PATENT	LITERATUR	E DOCUMEN	<u> </u>	
	T	Include name of the author (in C					
Examiner 's Initials*	Cite No. ¹	title of the item (book, magazine volume-issue number(s	, journal, se	erial, sympos	sium, catalo	g, etc.), date, page(s),	T ²
iiiuais							
							
ļ			 				
L	<u> </u>						

	1			
Examiner La	JaM.	Date	6/18/03	



JUN 1 3 2002

JUN 1 1 2002 4

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 4

a conceden of information unless it displays a	TVAIG CIVID CONTACT HUMBOT.
Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

U.S. PATENT DOCUMENTS						
		U.S. Patent Do	ocument		Data of Bublication	Bassa Calumaa Linna
Examiner	Cite		Kind Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines where relevant passage
Initials	No. ¹	Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant figures appea
	<u> </u>	· · · · · · · · · · · · · · · · · · ·				
	-	<u> </u>				
					1	
****			+	A CONTRACTOR OF THE CONTRACTOR		

FOREIGN PATENT DOCUMENTS

Initiale		Foreign	Patent Document	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
	Cite No.1	Office ³	Number ⁴ KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
K6		JP	JP11 19076	Pola Chemical Industrial Co., Ltd.	01-26-1999		Т
K6		JP	JP9227399	Pola Chemical Industrial Co., Ltd.	09-02-1997		Ŧ

Examiner	V + 11 C	Date	Clista
Signature	LateMa-	Considered	- lius

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



JUN 1 3 2002

PTO/SB/08A (08-00)

Approved for use thorn (1967) 16 (7904) 1749 (1951-1930) 2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 4

a collection of information unless it displays a	a valid OMB control number.
Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	
<u> </u>		WILLIAM J. CUNLIFFE, Acne, 1989, 1-11, Martin Dunitz Ltd., UK.	
		S. COHEN, T. KAMARCK, R. MERMELSTEIN, A Global Measure of Perceived Stress, Journal of Health and Social Behavior 1983, 385-396, Vol 24 (December).	
		P. BRANTLEY, C. WAGGONER, G. JONES, N. RAPPAPORT, A Daily Stress Inventory: Development, Reliability, and Validity, Journal of Behavioral Medicine,1987:61-75, Vol. 10, No.1.	
		T.R. COOPER, H.R. TRUNKFIELD, A.J. ZANELLA, W.D. BOOTH, An enzyme-linked Immunosorbent Assay for Cortisol in the Saliva of Man and Domestic Farm Animals, Journal of Endocrinology (1989) R13-R16.	
	•	A. BECK, G. BROWN, N. EPSTEIN, R. STEER, An Inventory for Measuring Clinical Anxiety: Psychometric Properties, Journal of Consulting and Clinical Psychology, 1988, 893-897, Vol. 56, No. 6.	
		A. BUSKE-KIRSCHBAUM, S. JOBST, A. WUSTMANS, C. KIRSCHBAUM, W. RAUH, D. HELLHAMMER, Attenuated Free Cortisol Response to Psychosocial Stress in Children with Atopic Dermatitis, Psychosomatic Medicine, 1997:419-426, Vol. 59.	
		A. SLOMINSKI, J. WORTSMAN, T. LUGER, R. PAUS, S. SOLOMON, Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress, Physiological Reviews, July 2000:979-1020.Vol. 80, No.3.	
		M. MOROHASHI, M. TOYADA, Y. LUO, S. HIGAKI, Cutaneous Neurologic Factors are Involved in the Pathogenesis of Acne, The Journal of Investigative Dermatology:820.,2000, Vol. 114 (Abstract)	
		E. AARDAL, A. CHARLOTTE HOLM, Cortisol in Saliva-Reference Ranges and Relation to Cortisol in Serum, European Journal Clin Chem, Clin Biochem 1995: 927-932, 33(No 12).	
		D. WATSON, L. CLARK, A. TELLEGEN, Development and Validation of Brief Measures of Positive and Negative Affect: The PANAS Scales, Journal of Personality and Social Psychology, 1988:1063-1070, Vol.54, No. 6.	
		O. WOLKOWITZ, V. REUS, A. KEEBLER, N. NELSON, M. FRIEDLAND, L. BRIZENDINE, E. ROBERTS, Double-Blind Treatment of Major Depression with Dehydroepiandrosterone, Am. J. Psychiatry, April 1999: 646-649, 156:4.	
		F. DHABHAR, B. MCEWEN, Enhancing versus suppressive effects of stress hormones on skin immune function, Proc. Natl. Acad. Sci. USA. 6(February 1999):1059-1064.,Vol. 96.	
		P. SCHULZ, W. SCHLOTZ, Trierer Inventar zur Erfassung von chronischem Streß (TICS), , Diagnostica 45, Heft 1, Hogrefe Veriag Gottingen 1999: 8-19	
]		M. HOROWTIZ, N. WILNER, W. ALVAREZ, Impact of Event Scale: A Measure of Subjective Stress, , Psychosomatic Medicine, (May 1979):209-218, Vol 41, No. 3.	
KG		P. HUNT, E. GURNELL, F. HUPPERT, C. RICHARDS, A. PREVOST, J. WASS, J. HERBERT, V. CHATTERJEE, Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison's Disease in a Randomized, Double Blind Trial, The Journal of Clincial Endocrinology & Metabolism, 2000:4650-4656, Vol 85, No. 12.	

Examiner	V 1 1 1 1 1 1	Date
Signature	Kufen C-	Considered 6.63.63

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



JUN 1 3 2002

Approved for us

~U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

JUN 1 1 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 4

a collection of information unless it displays a	valid OMB control number.
Application Number	10/017,180
Filing Date	December 7, 2001
First Named Inventor	Wiegand
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	JBP-571

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
166		M. CHREN, R. LASEK, S. FLOCKE, S. ZYZANSKI, Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases, Arch Dermaology, Nov. 1997:1433-1440, Vol 133.	
		J. KABAT-ZINN, E. WHEELER, T. LIGHT, A. SKILLINGS, M. SCHARF, T. CROPLEY, D. HOSMER, J BERNHARD, Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients with Moderate to Severe Psoriasis Undergoing Phototherapy (UVB) and Photochemotherapy(PUVA), Psychosomatic Medicine (1998):625-632, Vol. 60.	
		J. KIECOLT-GLASER, R. GLASER, E. STRAIN, J. STOUT, K. TARR, J. HOLLIDAY, C. SPEICHER, Modulation of Cellular Immunity in Medical Students, Journal of Behavioral Medicine, (1986):5-21., Vol.9, No. 1.	
		N. BOLGER, E. SCHILLING, Personality and the Problems of Everyday Life: The Role of Neuroticism in Exposure and Reactivity to Daily Stressors, Journal of Personality, September 1991: 355-386, 59:3.	
		M. SULZBERGER, S. ZAIDENS, Psychogenic Factors in Dermatologic Disorders, 1948:669-685. A. GARG, M. CHREN, L. SANDS, M. MATSUI, K. MARENUS, K. FEINGOLD, P. ELIAS, Psychological Stress Perturbs Epidermal Permeability Barrier Homeostasis, Implications for the Pathogenesis of Stress-Assoicated Skin Disorders, Arch Dermatol, (Jan 2001)53-59., Vol. 137.	.
		E. PANCONSESI, G. HAUTMANN, Psychophysiology of Stress in Dermatology: The Psychobiologic Pattern of Psychosomatics, Dermatologic Clinics, (July 1996):399-421., Vol. 14, Number 3.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychobiological Research:An Overview, Neuropsychobiology 1989:150-169, Vol. 22.	
		C. KIRSCHBAUM, D. HELLHAMMER, Salivary Cortisol in Psychoneuroendocrine Research:Recent Developments and Applications, Psychoneuroendocrinology, 1994, 313-333, Vol 19, No. 4.	
		M. DENDA, T. TSUCHIYA, P. ELIAS, K. FEINGOLD, Stress alters cutaneous permeability barrier homeostatis, Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2000:R367-R372., Vo. 278.	
		R. A. DRESSENDORFER, C. KIRSCHBAUM, W. ROHDE, F. STAHL, C.J. STRASBURGER, Synthesis of a Cortisol-Biotin Conjugate and Evaluation as a Tracer in an Immunoassay for Salivary Cortisol Measurement, J. Steroid Biochem, Molec. Biol. 1992, 683-692, Vol 43, no. 7.	
16		A. DELONGIS, S. FOLKMAN, R. LAZARUS, The Impact of Daily Stress on Health and Mood:Psychological and Social Resources as Mediators, Journal of Personality and Social Psychology, 1988:486-495, Vol 54, No. 3.	

Examiner Signature	KatuM. a	Date Gonsidered 6.19.13	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JUN 1 3 2002

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

JUN 1 1 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 4 of 4

a collection of information unless it displays a valid OMB control number.			
Application Number	10/017,180		
Filing Date	December 7, 2001		
First Named Inventor	Wiegand		
Group Art Unit	1614		
Examiner Name			
Attorney Docket Number	JBP-571		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
KG		G. CHROUSOS, P. GOLD, The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis, Stress and Stress Disorders-Chrousos & Gold, JAMA, March 4, 1992:1244-1252.Vol. 267, No. 9.	
1		R. SAPOLSKY, Why Zebras Don't Get Ulcers, W. H. Freeman and Company, New York, 1998:1-18.	
		TAUSK ET AL., Stress and the Skin, Arch Dermatol. Jan 2001:78-82, Vol. 137.	
		SCHOLZEN, T., ARMSTRONG, C.A., BUNNETT, N.W., LUGER, T. A., OLERUD, J.E., ANSEL, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system, Experimental Dermatology, 1998:7:81-96, Denmark.	
KG		www.shiseido.co. , publicly available prior to December 7, 2001.	
		·	

Examiner Signature	Date Considered	6-19-63
Cignature	Contadored	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington,

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.